1 Alzheimer's Association. 2021 Alzheimer's disease facts and figures. Alzheimer's & dementia : the journal of the Alzheimer's Association17, 327-406, doi:10.1002/alz.12328 (2021).
2 Ferretti, M. T. et al. Sex differences in Alzheimer disease - the gateway to precision medicine. Nature reviews. Neurology14, 457-469, doi:10.1038/s41582-018-0032-9 (2018).
3 Rahman, A. et al. Sex and Gender Driven Modifiers of Alzheimer's: The Role for Estrogenic Control Across Age, Race, Medical, and Lifestyle Risks. Front Aging Neurosci11, 315, doi:10.3389/fnagi.2019.00315 (2019).
4 Jett, S. et al. Endogenous and Exogenous Estrogen Exposures: How Women’s Reproductive Health Can Drive Brain Aging and Inform Alzheimer’s Prevention. Frontiers in Aging Neuroscience14, doi:10.3389/fnagi.2022.831807 (2022).
5 Altmann, A., Tian, L., Henderson, V. W., Greicius, M. D. & Alzheimer's Disease Neuroimaging Initiative, I. Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol75, 563-573, doi:10.1002/ana.24135 (2014).
6 Farrer, L. A. et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. Jama278, 1349-1356 (1997).
7 Brinton, R. D., Yao, J., Yin, F., Mack, W. J. & Cadenas, E. Perimenopause as a neurological transition state. Nat Rev Endocrinol11, 393-405, doi:10.1038/nrendo.2015.82
10.1038/nrendo.2015.82. Epub 2015 May 26. (2015).
8 Sperling, R. A., Karlawish, J. & Johnson, K. A. Preclinical Alzheimer disease—the challenges ahead. Nature Reviews Neurology9, 54-58, doi:10.1038/nrneurol.2012.241 (2013).
9 Mosconi, L. et al. Correction: Perimenopause and emergence of an Alzheimer's bioenergetic phenotype in brain and periphery. PLoS One13, e0193314, doi:10.1371/journal.pone.0193314 (2018).
10 Mosconi, L. et al. Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging. Neurology89, 1382-1390, doi:10.1212/wnl.0000000000004425 (2017).
11 Mosconi, L. et al. Increased Alzheimer's risk during the menopause transition: A 3-year longitudinal brain imaging study. PLoS One13, e0207885, doi:10.1371/journal.pone.0207885 (2018).
12 Mosconi, L. et al. Menopause impacts human brain structure, connectivity, energy metabolism, and amyloid-beta deposition. Sci Rep11, 10867, doi:10.1038/s41598-021-90084-y (2021).
13 Rahman, A. et al. Sex-driven modifiers of Alzheimer risk. Neurology95, e166, doi:10.1212/WNL.0000000000009781 (2020).
14 Schelbaum, E. et al. Association of Reproductive History With Brain MRI Biomarkers of Dementia Risk in Midlife. Neurology, 10.1212/WNL.0000000000012941, doi:10.1212/wnl.0000000000012941 (2021).
15 Ding, F., Yao, J., Rettberg, J. R., Chen, S. & Brinton, R. D. Early decline in glucose transport and metabolism precedes shift to ketogenic system in female aging and Alzheimer's mouse brain: implication for bioenergetic intervention. PLoS One8, e79977, doi:10.1371/journal.pone.0079977 (2013).
16 Yin, F. et al. The perimenopausal aging transition in the female rat brain: decline in bioenergetic systems and synaptic plasticity. Neurobiol Aging36, 2282-2295, doi:10.1016/j.neurobiolaging.2015.03.013 (2015).
17 Yao, J., Chen, S., Mao, Z., Cadenas, E. & Brinton, R. D. 2-Deoxy-D-glucose treatment induces ketogenesis, sustains mitochondrial function, and reduces pathology in female mouse model of Alzheimer's disease. PLoS One6, e21788, doi:10.1371/journal.pone.0021788 (2011).
18 Wang, Y. et al. Midlife Chronological and Endocrinological Transitions in Brain Metabolism: System Biology Basis for Increased Alzheimer’s Risk in Female Brain. Sci Rep10, 8528, doi:10.1038/s41598-020-65402-5 (2020).
19 Yao, J. et al. Ovarian hormone loss induces bioenergetic deficits and mitochondrial beta-amyloid. Neurobiol Aging33, 1507-1521, doi:10.1016/j.neurobiolaging.2011.03.001 (2012).
20 Lin, M. T. & Beal, M. F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature443, 787-795, doi:10.1038/nature05292 (2006).
21 Gibson, G. E. & Shi, Q. A mitocentric view of Alzheimer’s disease suggests multi-faceted treatments. J Alzheimers Dis20, S591 (2010).
22 Swerdlow, R. H. Mitochondria and Mitochondrial Cascades in Alzheimer's Disease. J Alzheimers Dis62, 1403-1416, doi:10.3233/JAD-170585 (2018).
23 Pratico, D., Uryu, K., Leight, S., Trojanoswki, J. Q. & Lee, V. M. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci21, 4183-4187 (2001).
24 Chaumeil, M. M. et al. Multimodal neuroimaging provides a highly consistent picture of energy metabolism, validating 31P MRS for measuring brain ATP synthesis. Proc Natl Acad Sci U S A106, 3988-3993, doi:10.1073/pnas.0806516106 (2009).
25 Du, F., Zhu, X. H., Qiao, H., Zhang, X. & Chen, W. Efficient in vivo 31P magnetization transfer approach for noninvasively determining multiple kinetic parameters and metabolic fluxes of ATP metabolism in the human brain. Magnetic resonance in medicine57, 103-114, doi:10.1002/mrm.21107 (2007).
26 Du, F. et al. Tightly coupled brain activity and cerebral ATP metabolic rate. Proc Natl Acad Sci U S A105, 6409-6414, doi:10.1073/pnas.0710766105 (2008).
27 Das, N., Ren, J., Spence, J. & Chapman, S. B. Phosphate Brain Energy Metabolism and Cognition in Alzheimer's Disease: A Spectroscopy Study Using Whole-Brain Volume-Coil (31)Phosphorus Magnetic Resonance Spectroscopy at 7Tesla. Front Neurosci15, 641739, doi:10.3389/fnins.2021.641739 (2021).
28 Rijpma, A., van der Graaf, M., Meulenbroek, O., Olde Rikkert, M. G. M. & Heerschap, A. Altered brain high-energy phosphate metabolism in mild Alzheimer's disease: A 3-dimensional (31)P MR spectroscopic imaging study. Neuroimage Clin18, 254-261, doi:10.1016/j.nicl.2018.01.031 (2018).
29 Mecheri, G. et al. In vivo hippocampal (31)P NMR metabolites in Alzheimer's disease and ageing. Eur Psychiatry12, 140-148, doi:10.1016/s0924-9338(97)80203-9 (1997).
30 Mandal, P. K., Akolkar, H. & Tripathi, M. Mapping of hippocampal pH and neurochemicals from in vivo multi-voxel 31P study in healthy normal young male/female, mild cognitive impairment, and Alzheimer's disease. Journal of Alzheimer's disease : JAD31 Suppl 3, S75-86, doi:10.3233/JAD-2012-120166 (2012).
31 Nitsch, R. M. et al. Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci U S A89, 1671-1675, doi:10.1073/pnas.89.5.1671 (1992).
32 Pettegrew, J. W., Panchalingam, K., Hamilton, R. L. & McClure, R. J. Brain membrane phospholipid alterations in Alzheimer's disease. Neurochem Res26, 771-782, doi:10.1023/a:1011603916962 (2001).
33 Sundermann, E. E. et al. Does the Female Advantage in Verbal Memory Contribute to Underestimating Alzheimer's Disease Pathology in Women versus Men? Journal of Alzheimer's disease : JAD56, 947-957, doi:10.3233/jad-160716 (2017).
34 Koran, M. E. I., Wagener, M. & Hohman, T. J. Sex differences in the association between AD biomarkers and cognitive decline. Brain Imaging Behav11, 205-213, doi:10.1007/s11682-016-9523-8 (2017).
35 Buckley, R. F. et al. Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. Alzheimer's & dementia : the journal of the Alzheimer's Association14, 1193-1203, doi:10.1016/j.jalz.2018.04.010 (2018).
36 Hua, X. et al. Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans. Neurobiol Aging31, 1463-1480, doi:10.1016/j.neurobiolaging.2010.04.033 (2010).
37 Skup, M. et al. Sex differences in grey matter atrophy patterns among AD and aMCI patients: results from ADNI. NeuroImage56, 890-906, doi:10.1016/j.neuroimage.2011.02.060 (2011).
38 Sundermann, E. E. et al. Women's higher brain metabolic rate compensates for early Alzheimer's pathology. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring12, e12121, doi:https://doi.org/10.1002/dad2.12121 (2020).
39 Rietzler, A. et al. Energy metabolism measured by 31P magnetic resonance spectroscopy in the healthy human brain. J Neuroradiol, doi:10.1016/j.neurad.2021.11.006 (2021).
40 Smith, C. D. et al. Frontal lobe phosphorus metabolism and neuropsychological function in aging and in Alzheimer's disease. Ann Neurol38, 194-201, doi:10.1002/ana.410380211 (1995).
41 Bottomley, P. A. et al. Alzheimer dementia: quantification of energy metabolism and mobile phosphoesters with P-31 NMR spectroscopy. Radiology183, 695-699, doi:10.1148/radiology.183.3.1584923 (1992).
42 Pettegrew, J. W., Panchalingam, K., Klunk, W. E., McClure, R. J. & Muenz, L. R. Alterations of cerebral metabolism in probable Alzheimer's disease: a preliminary study. Neurobiol Aging15, 117-132, doi:10.1016/0197-4580(94)90152-x (1994).
43 Song, T. et al. Mitochondrial dysfunction, oxidative stress, neuroinflammation, and metabolic alterations in the progression of Alzheimer’s disease: A meta-analysis of in vivo magnetic resonance spectroscopy studies. Ageing Research Reviews72, 101503, doi:https://doi.org/10.1016/j.arr.2021.101503 (2021).
44 Forlenza, O. V. et al. Reduced phospholipid breakdown in Alzheimer's brains: a 31P spectroscopy study. Psychopharmacology (Berl)180, 359-365, doi:10.1007/s00213-005-2168-8 (2005).
45 Jack, C. R., Jr. et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. The Lancet. Neurology12, 207-216, doi:10.1016/S1474-4422(12)70291-0 (2013).
46 Mosconi, L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging32, 486-510, doi:10.1007/s00259-005-1762-7 (2005).
47 Brinton, R. D. The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. Trends Neurosci31, 529-537, doi:10.1016/j.tins.2008.07.003 (2008).
48 Azcoitia, I., Fernandez-Galaz, C., Sierra, A. & Garcia-Segura, L. M. Gonadal hormones affect neuronal vulnerability to excitotoxin-induced degeneration. J Neurocytol28, 699-710, doi:10.1023/a:1007025219044 (1999).
49 Yue, X. et al. Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. Proc Natl Acad Sci U S A102, 19198-19203, doi:10.1073/pnas.0505203102 (2005).
50 Morrison, J. H., Brinton, R. D., Schmidt, P. J. & Gore, A. C. Estrogen, Menopause, and the Aging Brain: How Basic Neuroscience Can Inform Hormone Therapy in Women. The Journal of Neuroscience26, 10332-10348, doi:10.1523/jneurosci.3369-06.2006 (2006).
51 Lejri, I., Grimm, A. & Eckert, A. Mitochondria, Estrogen and Female Brain Aging. Frontiers in Aging Neuroscience10, doi:10.3389/fnagi.2018.00124 (2018).
52 Klosinski, L. P. et al. White Matter Lipids as a Ketogenic Fuel Supply in Aging Female Brain: Implications for Alzheimer's Disease. EBioMedicine2, 1888-1904, doi:10.1016/j.ebiom.2015.11.002 (2015).
53 Yao, J., Rettberg, J. R., Klosinski, L. P., Cadenas, E. & Brinton, R. D. Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions. Mol Aspects Med32, 247-257, doi:10.1016/j.mam.2011.10.005 (2011).
54 Gonzalez, R. G. et al. Quantitative in vivo 31P magnetic resonance spectroscopy of Alzheimer disease. Alzheimer disease and associated disorders10, 46-52 (1996).
55 Goyal, M. S. Correction for Goyal et al., Persistent metabolic youth in the aging female brain. Proceedings of the National Academy of Sciences116, 5198-5198, doi:10.1073/pnas.1902264116 (2019).
56 Vlassenko, A. G. et al. Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ) deposition. Proceedings of the National Academy of Sciences107, 17763-17767 (2010).
57 Chance, B., Eleff, S., Leigh, J. S., Jr., Sokolow, D. & Sapega, A. Mitochondrial regulation of phosphocreatine/inorganic phosphate ratios in exercising human muscle: a gated 31P NMR study. Proc Natl Acad Sci U S A78, 6714-6718, doi:10.1073/pnas.78.11.6714 (1981).
58 Henchcliffe, C. et al. Multinuclear Magnetic Resonance Spectroscopy for in Vivo Assessment of Mitochondrial Dysfunction in Parkinson's Disease. Annals of the New York Academy of Sciences1147, 206-220, doi:https://doi.org/10.1196/annals.1427.037 (2008).
59 Weiduschat, N. et al. Sex differences in cerebral energy metabolism in Parkinson's disease: a phosphorus magnetic resonance spectroscopic imaging study. Parkinsonism Relat Disord20, 545-548, doi:10.1016/j.parkreldis.2014.02.003 (2014).
60 Meyerspeer, M. et al. (31) P magnetic resonance spectroscopy in skeletal muscle: Experts' consensus recommendations. NMR Biomed, e4246, doi:10.1002/nbm.4246 (2020).
61 Petersen, R. C. et al. Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. JAMA Neurol73, 85-92, doi:10.1001/jamaneurol.2015.3098 (2016).
62 Levine, M. E. et al. Menopause accelerates biological aging. Proceedings of the National Academy of Sciences113, 9327-9332, doi:10.1073/pnas.1604558113 (2016).
63 Harlow, S. D. et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause19, 387-395, doi:10.1097/gme.0b013e31824d8f40 (2012).
64 Maki, P. M. & Henderson, V. W. Cognition and the menopause transition. Menopause23, 803-805, doi:10.1097/gme.0000000000000681 (2016).
65 Ashburner, J. & Friston, K. J. Voxel-based morphometry--the methods. NeuroImage11, 805-821, doi:10.1006/nimg.2000.0582 (2000).
66 Desikan, R. S. et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. NeuroImage31, 968-980, doi:10.1016/j.neuroimage.2006.01.021 (2006).
67 Fischl, B. FreeSurfer. NeuroImage62, 774-781, doi:10.1016/j.neuroimage.2012.01.021 (2012).
68 Vlassenko, A. G. et al. Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. Annals of neurology80, 379-387, doi:10.1002/ana.24719 (2016).
69 Mintun, M. A. et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology67, 446-452, doi:10.1212/01.wnl.0000228230.26044.a4 (2006).